| Amanda Beth Johnson, DO | |
|
140 Burke Calhoun City Rd, Calhoun City, MS 38916-9690 | |
| (662) 628-6622 | |
| Not Available |
| Full Name | Amanda Beth Johnson |
|---|---|
| Gender | Female |
| Speciality | Interventional Radiology |
| Experience | 14 Years |
| Location | 140 Burke Calhoun City Rd, Calhoun City, Mississippi |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942511456 | NPI | - | NPPES |
| FY7AZ | Other | FL | FL BLUE PROVIDER NUMBER |
| 04385321 | Medicaid | MS |
| Facility Name | Location | Facility Type |
|---|---|---|
| North Mississippi Medical Center | Tupelo, MS | Hospital |
| North Mississippi Medical Center-gilmore Amory | Amory, MS | Hospital |
| Tishomingo Health Services Inc | Iuka, MS | Hospital |
| Webster General Hospital/ Swing Bed | Eupora, MS | Hospital |
| Pontotoc Health Service Inc Cah | Pontotoc, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Premier Radiology Inc | 2769452242 | 20 |
| Baptist Memorial Hospital-calhoun Inc | 5395024210 | 20 |
| Medical Imaging, Llc | 5698731271 | 15 |
| Imaging Center At Gloster Creek Village Pllc | 5991771255 | 15 |
| Tate County Hospital | 6103282165 | 22 |
News Archive
Italian study results confirm that a multivariate serum protein test predicts improved survival after treatment with chemotherapy versus erlotinib for non-small-cell lung cancer, but only among patients who are likely to have a poor outcome with the latter treatment type.
Two types of blood pressure medications -; alpha blockers and alpha 2 agonist -; show increased variability in blood pressure measurements between doctor visits, which is associated with an increased risk of death, according to new research from the Intermountain Medical Center Heart Institute in Salt Lake City.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a biological therapy with a mechanism of action other than tumor necrosis factor alpha (TNF-alpha) inhibition for the treatment of moderate to severe ulcerative colitis, would earn a 25 percent patient share according to surveyed U.S. gastroenterologists. Similarly, in Europe, such an agent would also earn 25 percent patient share according to surveyed European gastroenterologists.
Zylast products have been selected as one of only three initial winners of the USAID Fighting Ebola Grand Challenge. The announcement, made from the White House, introduces Zylast as a solution to "help healthcare workers on the front lines provide better care and stop the spread of Ebola."
› Verified 5 days ago
| Entity Name | Premier Radiology Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083669121 PECOS PAC ID: 2769452242 Enrollment ID: O20040730000681 |
News Archive
Italian study results confirm that a multivariate serum protein test predicts improved survival after treatment with chemotherapy versus erlotinib for non-small-cell lung cancer, but only among patients who are likely to have a poor outcome with the latter treatment type.
Two types of blood pressure medications -; alpha blockers and alpha 2 agonist -; show increased variability in blood pressure measurements between doctor visits, which is associated with an increased risk of death, according to new research from the Intermountain Medical Center Heart Institute in Salt Lake City.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a biological therapy with a mechanism of action other than tumor necrosis factor alpha (TNF-alpha) inhibition for the treatment of moderate to severe ulcerative colitis, would earn a 25 percent patient share according to surveyed U.S. gastroenterologists. Similarly, in Europe, such an agent would also earn 25 percent patient share according to surveyed European gastroenterologists.
Zylast products have been selected as one of only three initial winners of the USAID Fighting Ebola Grand Challenge. The announcement, made from the White House, introduces Zylast as a solution to "help healthcare workers on the front lines provide better care and stop the spread of Ebola."
› Verified 5 days ago
| Entity Name | Imaging Center At Gloster Creek Village Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417907536 PECOS PAC ID: 5991771255 Enrollment ID: O20040908000606 |
News Archive
Italian study results confirm that a multivariate serum protein test predicts improved survival after treatment with chemotherapy versus erlotinib for non-small-cell lung cancer, but only among patients who are likely to have a poor outcome with the latter treatment type.
Two types of blood pressure medications -; alpha blockers and alpha 2 agonist -; show increased variability in blood pressure measurements between doctor visits, which is associated with an increased risk of death, according to new research from the Intermountain Medical Center Heart Institute in Salt Lake City.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a biological therapy with a mechanism of action other than tumor necrosis factor alpha (TNF-alpha) inhibition for the treatment of moderate to severe ulcerative colitis, would earn a 25 percent patient share according to surveyed U.S. gastroenterologists. Similarly, in Europe, such an agent would also earn 25 percent patient share according to surveyed European gastroenterologists.
Zylast products have been selected as one of only three initial winners of the USAID Fighting Ebola Grand Challenge. The announcement, made from the White House, introduces Zylast as a solution to "help healthcare workers on the front lines provide better care and stop the spread of Ebola."
› Verified 5 days ago
| Entity Name | Medical Imaging, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316075864 PECOS PAC ID: 5698731271 Enrollment ID: O20041206000515 |
News Archive
Italian study results confirm that a multivariate serum protein test predicts improved survival after treatment with chemotherapy versus erlotinib for non-small-cell lung cancer, but only among patients who are likely to have a poor outcome with the latter treatment type.
Two types of blood pressure medications -; alpha blockers and alpha 2 agonist -; show increased variability in blood pressure measurements between doctor visits, which is associated with an increased risk of death, according to new research from the Intermountain Medical Center Heart Institute in Salt Lake City.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a biological therapy with a mechanism of action other than tumor necrosis factor alpha (TNF-alpha) inhibition for the treatment of moderate to severe ulcerative colitis, would earn a 25 percent patient share according to surveyed U.S. gastroenterologists. Similarly, in Europe, such an agent would also earn 25 percent patient share according to surveyed European gastroenterologists.
Zylast products have been selected as one of only three initial winners of the USAID Fighting Ebola Grand Challenge. The announcement, made from the White House, introduces Zylast as a solution to "help healthcare workers on the front lines provide better care and stop the spread of Ebola."
› Verified 5 days ago
| Entity Name | Tippah County Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891720009 PECOS PAC ID: 5193746709 Enrollment ID: O20051212000167 |
News Archive
Italian study results confirm that a multivariate serum protein test predicts improved survival after treatment with chemotherapy versus erlotinib for non-small-cell lung cancer, but only among patients who are likely to have a poor outcome with the latter treatment type.
Two types of blood pressure medications -; alpha blockers and alpha 2 agonist -; show increased variability in blood pressure measurements between doctor visits, which is associated with an increased risk of death, according to new research from the Intermountain Medical Center Heart Institute in Salt Lake City.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a biological therapy with a mechanism of action other than tumor necrosis factor alpha (TNF-alpha) inhibition for the treatment of moderate to severe ulcerative colitis, would earn a 25 percent patient share according to surveyed U.S. gastroenterologists. Similarly, in Europe, such an agent would also earn 25 percent patient share according to surveyed European gastroenterologists.
Zylast products have been selected as one of only three initial winners of the USAID Fighting Ebola Grand Challenge. The announcement, made from the White House, introduces Zylast as a solution to "help healthcare workers on the front lines provide better care and stop the spread of Ebola."
› Verified 5 days ago
| Entity Name | Imaging Centers For Excellence, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730281148 PECOS PAC ID: 6406854538 Enrollment ID: O20061127000362 |
News Archive
Italian study results confirm that a multivariate serum protein test predicts improved survival after treatment with chemotherapy versus erlotinib for non-small-cell lung cancer, but only among patients who are likely to have a poor outcome with the latter treatment type.
Two types of blood pressure medications -; alpha blockers and alpha 2 agonist -; show increased variability in blood pressure measurements between doctor visits, which is associated with an increased risk of death, according to new research from the Intermountain Medical Center Heart Institute in Salt Lake City.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a biological therapy with a mechanism of action other than tumor necrosis factor alpha (TNF-alpha) inhibition for the treatment of moderate to severe ulcerative colitis, would earn a 25 percent patient share according to surveyed U.S. gastroenterologists. Similarly, in Europe, such an agent would also earn 25 percent patient share according to surveyed European gastroenterologists.
Zylast products have been selected as one of only three initial winners of the USAID Fighting Ebola Grand Challenge. The announcement, made from the White House, introduces Zylast as a solution to "help healthcare workers on the front lines provide better care and stop the spread of Ebola."
› Verified 5 days ago
| Entity Name | Oxford Pre Op & Imaging Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750646436 PECOS PAC ID: 0840444998 Enrollment ID: O20130125000383 |
News Archive
Italian study results confirm that a multivariate serum protein test predicts improved survival after treatment with chemotherapy versus erlotinib for non-small-cell lung cancer, but only among patients who are likely to have a poor outcome with the latter treatment type.
Two types of blood pressure medications -; alpha blockers and alpha 2 agonist -; show increased variability in blood pressure measurements between doctor visits, which is associated with an increased risk of death, according to new research from the Intermountain Medical Center Heart Institute in Salt Lake City.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a biological therapy with a mechanism of action other than tumor necrosis factor alpha (TNF-alpha) inhibition for the treatment of moderate to severe ulcerative colitis, would earn a 25 percent patient share according to surveyed U.S. gastroenterologists. Similarly, in Europe, such an agent would also earn 25 percent patient share according to surveyed European gastroenterologists.
Zylast products have been selected as one of only three initial winners of the USAID Fighting Ebola Grand Challenge. The announcement, made from the White House, introduces Zylast as a solution to "help healthcare workers on the front lines provide better care and stop the spread of Ebola."
› Verified 5 days ago
| Entity Name | Choctaw Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235547878 PECOS PAC ID: 2567682206 Enrollment ID: O20141215002502 |
News Archive
Italian study results confirm that a multivariate serum protein test predicts improved survival after treatment with chemotherapy versus erlotinib for non-small-cell lung cancer, but only among patients who are likely to have a poor outcome with the latter treatment type.
Two types of blood pressure medications -; alpha blockers and alpha 2 agonist -; show increased variability in blood pressure measurements between doctor visits, which is associated with an increased risk of death, according to new research from the Intermountain Medical Center Heart Institute in Salt Lake City.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a biological therapy with a mechanism of action other than tumor necrosis factor alpha (TNF-alpha) inhibition for the treatment of moderate to severe ulcerative colitis, would earn a 25 percent patient share according to surveyed U.S. gastroenterologists. Similarly, in Europe, such an agent would also earn 25 percent patient share according to surveyed European gastroenterologists.
Zylast products have been selected as one of only three initial winners of the USAID Fighting Ebola Grand Challenge. The announcement, made from the White House, introduces Zylast as a solution to "help healthcare workers on the front lines provide better care and stop the spread of Ebola."
› Verified 5 days ago
| Entity Name | Baptist Memorial Hospital-calhoun Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881142461 PECOS PAC ID: 5395024210 Enrollment ID: O20161203000022 |
News Archive
Italian study results confirm that a multivariate serum protein test predicts improved survival after treatment with chemotherapy versus erlotinib for non-small-cell lung cancer, but only among patients who are likely to have a poor outcome with the latter treatment type.
Two types of blood pressure medications -; alpha blockers and alpha 2 agonist -; show increased variability in blood pressure measurements between doctor visits, which is associated with an increased risk of death, according to new research from the Intermountain Medical Center Heart Institute in Salt Lake City.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a biological therapy with a mechanism of action other than tumor necrosis factor alpha (TNF-alpha) inhibition for the treatment of moderate to severe ulcerative colitis, would earn a 25 percent patient share according to surveyed U.S. gastroenterologists. Similarly, in Europe, such an agent would also earn 25 percent patient share according to surveyed European gastroenterologists.
Zylast products have been selected as one of only three initial winners of the USAID Fighting Ebola Grand Challenge. The announcement, made from the White House, introduces Zylast as a solution to "help healthcare workers on the front lines provide better care and stop the spread of Ebola."
› Verified 5 days ago
| Entity Name | Tate County Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285331298 PECOS PAC ID: 6103282165 Enrollment ID: O20230517000566 |
News Archive
Italian study results confirm that a multivariate serum protein test predicts improved survival after treatment with chemotherapy versus erlotinib for non-small-cell lung cancer, but only among patients who are likely to have a poor outcome with the latter treatment type.
Two types of blood pressure medications -; alpha blockers and alpha 2 agonist -; show increased variability in blood pressure measurements between doctor visits, which is associated with an increased risk of death, according to new research from the Intermountain Medical Center Heart Institute in Salt Lake City.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a biological therapy with a mechanism of action other than tumor necrosis factor alpha (TNF-alpha) inhibition for the treatment of moderate to severe ulcerative colitis, would earn a 25 percent patient share according to surveyed U.S. gastroenterologists. Similarly, in Europe, such an agent would also earn 25 percent patient share according to surveyed European gastroenterologists.
Zylast products have been selected as one of only three initial winners of the USAID Fighting Ebola Grand Challenge. The announcement, made from the White House, introduces Zylast as a solution to "help healthcare workers on the front lines provide better care and stop the spread of Ebola."
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amanda Beth Johnson, DO 620 Crossover Rd, Tupelo, MS 38801-4944 Ph: (850) 873-3990 | Amanda Beth Johnson, DO 140 Burke Calhoun City Rd, Calhoun City, MS 38916-9690 Ph: (662) 628-6622 |
News Archive
Italian study results confirm that a multivariate serum protein test predicts improved survival after treatment with chemotherapy versus erlotinib for non-small-cell lung cancer, but only among patients who are likely to have a poor outcome with the latter treatment type.
Two types of blood pressure medications -; alpha blockers and alpha 2 agonist -; show increased variability in blood pressure measurements between doctor visits, which is associated with an increased risk of death, according to new research from the Intermountain Medical Center Heart Institute in Salt Lake City.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a biological therapy with a mechanism of action other than tumor necrosis factor alpha (TNF-alpha) inhibition for the treatment of moderate to severe ulcerative colitis, would earn a 25 percent patient share according to surveyed U.S. gastroenterologists. Similarly, in Europe, such an agent would also earn 25 percent patient share according to surveyed European gastroenterologists.
Zylast products have been selected as one of only three initial winners of the USAID Fighting Ebola Grand Challenge. The announcement, made from the White House, introduces Zylast as a solution to "help healthcare workers on the front lines provide better care and stop the spread of Ebola."
› Verified 5 days ago
Dr. Robert A Duke, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 140 Burke Calhoun City Rd, Calhoun City, MS 38916 Phone: 662-628-6622 |